Publicaciones en colaboración con investigadores/as de National Cancer Center (4)

2020

  1. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    Journal of Hepatology, Vol. 73, Núm. 6, pp. 1460-1469

2019

  1. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 862-876

2017

  1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

2015

  1. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis

    International Journal of Radiation Oncology Biology Physics, Vol. 91, Núm. 1, pp. 133-139